All Articles by Author:

lbeveridge

CD20 CAR T-Cells Safely and Reversibly Ablate B-Cell Follicles in a Nonhuman Primate Model of HIV Persistence

[Molecular Therapy] In simian/human immunodeficiency virus (SHIV)-infected animals, CAR T cells were highly functional with rapid expansion and trafficking to tissue-associated viral sanctuaries including B cell follicles and gut-associated lymphoid tissues.

Stem Cell-Derived CAR T Cells Show Greater Persistence, Trafficking, and Plasma Viral Control Compared to Ex Vivo Transduced CAR T Cells In Vivo

[Molecular Therapy] Using the humanized bone marrow/liver/thymus mouse model and nonhuman primate model of HIV infection, scientists evaluated two CAR-based gene therapy approaches.

Nonsignaling Extracellular Spacer Regulates Tumor Antigen Selectivity of CAR T Cells

[Molecular Therapy Oncology] Investigators developed a CAR T cell therapy targeting prostate stem cell antigen for prostate and pancreatic cancers, showing improved pre-clinical antitumor activity and T cell persistence by optimizing the intracellular co-stimulatory domain.

Idecabtagene Vicleucel Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory Multiple Myeloma With Renal Impairment

[Haematologica] Scientists evaluated patients with relapsed multiple myeloma with renal impairment treated with standard of care idecabtagene vicleucel, as outcomes with CAR T cell therapy are unknown in this population.

Emerging Strategies for Nanomedicine in Autoimmunity

[Advanced Drug Delivery Reviews] Investigators focus on leveraging the power of nanomedicine for prevalent autoimmune disorders throughout the body. They expand on three key areas for the development of autoimmunity therapies— avoiding systemic immunosuppression, balancing interactions with the immune system, and elevating current platforms for delivering complex cargoes.

CAR T Therapies in Multiple Myeloma: Unleashing the Future

[Cancer Gene Therapy] Ongoing preclinical and clinical trials are exploring the capabilities of CAR T cells in targeting specific antigens on myeloma cells, offering hope for patients with relapsed/refractory multiple myeloma.

Popular

A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer

[A2 Biotherapeutics, Inc.] A2 Biotherapeutics, Inc. announced that the US FDA has granted Orphan Drug Designation to A2B530 for the treatment of germline heterozygous patients with colorectal cancer that expresses carcinoembryonic antigen and has lost HLA-A*02 expression.

Intestinal Epithelial Krüppel-Like Factor 4 Alleviates Endotoxemia and Atherosclerosis through Improving NF-κB/miR-34a-Mediated Intestinal Permeability

[Acta Pharmacologica Sinica] The authors investigated the role of krüppel-like factor 4 in regulating intestinal inflammation and permeability during the atherosclerotic process.

Cancer Associated Fibroblasts-Derived SULF1 Promotes Gastric Cancer Metastasis and CDDP Resistance through the TGFBR3-Mediated TGF-β Signaling Pathway

[Cell Death Discovery] Scientists examined the role and underlying molecular mechanisms of human sulfatase 1 (SULF1) in the context of gastric cancer.